摘要
【目的】观察培美曲塞或紫杉醇联合顺铂治疗晚期非鳞非小细胞肺癌(NSCLC)的临床疗效及不良反应。【方法】回顾性分析我院晚期非鳞非小细胞肺癌患者41例,分为观察组19例,对照组22例。观察组采用培美曲塞联合顺铂化疗,对照组采用紫杉醇联合顺铂化疗。对两组患者临床治疗效果进行分析。【结果】观察组和对照组的客观缓解率分别为36.8%和31.8%,疾病控制率分别为73.7%和68.2%(P>0.05)。中位总生存期(OS)分别为11.7个月和10.1个月,1年生存率分别为34.6%和33.7%。培美曲塞组不良反应:白细胞降低、脱发、消化道反应等发生率低于对照组(P<0.05)。【结论】培美曲塞或紫杉醇联合顺铂治疗晚期非鳞非小细胞肺癌疗效相似,培美曲塞组不良反应的发生率较低,耐受性较好。
【Objective】To discuss the clinical efficacy and the adverse reactions of peme-trexed combined with cisplatin and paclitaxel combined with cisplatin in treating patients with advanced nonsquamous non-small cell lung cancer（NSCLC）.【Methods】Clinical data of 41 patients with advanced nonsquamous NSCLC treated in our hospital from January 2013 to March 2016 were reviewed. 19 patients received pemetrexed plus cisplatin and the other 22 patients received paclitaxel plus cisplatin. The efficacies and toxicities of the two groups were compared. Kaplan-Meier method was used for survival analysis.【Results】No statistical significance were found between the pemetrexed group and the paclitaxel group in the response rate（36.8% vs 31.8%）,the disease control rate（73.7% vs 68.2%）, the median overall survival（11.7vs 10.1months）, and the 1 year survival rate（34.6%vs 33.7%）（ P〉0.05）. The adverse reactions in the pemetrexed group were lower than those in the paclitaxel group（ P〈0.05）.【Conclusion】Pemetrexed combined with cisplatin has the similar efficacy and less toxicities compared with paclitaxel combined with cisplatin in the treatment of advanced nonsquamous NSCLC.
作者
母丹
叶璐
付波
MU Dan YE Lu FU Bo(Department of Oncology, the Nuclear Industry 416 Hospital, Chengdu 610051)
出处
《武警后勤学院学报（医学版）》
CAS
2017年第6期493-495,共3页
Journal of Logistics University of PAP（Medical Sciences）
关键词
培美曲塞
紫杉醇
顺铂
晚期非鳞非小细胞肺癌
化疗
Pemetrexed
Paclitaxel
Cisplatin
Advanced nonsquamous non-small cell lung cancer
Chemotherapy
